AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33461181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr grating manufactured by LFAD
Number of subjects: 0
Study 33461181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cr grating and replicated grating (silicon grating)
Number of subjects: 0
Study 33228583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychotic disorders (n = 300)
Number of subjects: 351
Study 33228583 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 51)
Number of subjects: 351
Study 33228583 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with psychotic disorders
Number of subjects: 351
Study 33228583 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 351
Study 34047292 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophoresis using Depotphorese® device with calcium hydroxide plus copper paste (Cupral®), low current electric field (1.5 mA/min for 10 min).
Number of subjects: 30
Study 34047292 — intervention group
Group type: COMPARATOR
Intervention: Control group (without root canal preparation).
Number of subjects: 30
Study 32998731 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid agonist treatment (OAT)
Number of subjects: 62
Study 34895510 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed clamping (60 seconds or more)
Number of subjects: 1531
Study 34895510 — intervention group
Group type: COMPARATOR
Intervention: Immediate clamping (within 10 seconds)
Number of subjects: 1531
Study 34895510 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed clamping
Number of subjects: 1531
Study 34895510 — intervention group
Group type: COMPARATOR
Intervention: Immediate clamping
Number of subjects: 1531
Study 33823815 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intake of 300 ml carbohydrate solution (CH group)
Number of subjects: 120
Study 33823815 — intervention group
Group type: COMPARATOR
Intervention: Oral intake of 300 ml pure water (PW group)
Number of subjects: 120
Study 33823815 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 8 h before surgery (F group)
Number of subjects: 120
Study 32125980 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) underwent nine sessions of repeated heat exposure at high temperatures (100 °C, 20% RH) for three weeks (HEHT)
Number of subjects: 29
Study 32125980 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 29
Study 36894666 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional cementation strategy (CRC group: adhesive system + resin cement) (Adper Single Bond + RelyX ARC; 3 M‐ESPE)
Number of subjects: 152
Study 36894666 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive cementation strategy (SRC group: self-adhesive resin cement; RelyX U100/U200; 3 M‐ESPE)
Number of subjects: 152
Study 36894666 — intervention group
Group type: COMPARATOR
Intervention: Control group (CRC)
Number of subjects: 152
Study 36894666 — intervention group
Group type: COMPARATOR
Intervention: Control group (SRC)
Number of subjects: 152
Study 33277648 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depleting drink
Number of subjects: 25
Study 33277648 — intervention group
Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 25
Study 36345697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinone 2% cream + 755-nm picosecond laser
Number of subjects: 20
Study 36345697 — intervention group
Group type: COMPARATOR
Intervention: Hydroquinone 2% cream alone
Number of subjects: 20
Study 33881335 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of obstetric danger signs
Number of subjects: 1624
Study 33881335 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of need for antenatal care
Number of subjects: 1624
Study 33881335 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of need for facility delivery
Number of subjects: 1624
Study 34610971 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 and lurbinectedin 3.0-5.0 mg (escalation phase)
Number of subjects: 34
Study 34610971 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 40 mg/m2 and lurbinectedin 2.0 mg/m2 (expansion cohort)
Number of subjects: 34
Study 34610971 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin and lurbinectedin (both cohorts)
Number of subjects: 34
Study 32779375 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-particle hyaluronic acid (SP-HA)
Number of subjects: 10
Study 32779375 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-particle hyaluronic acid (LP-HA)
Number of subjects: 10
Study 35945093 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal CRB‐tDCS
Number of subjects: 40
Study 35945093 — intervention group
Group type: COMPARATOR
Intervention: Sham CRB‐tDCS
Number of subjects: 40
Study 34429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, orally, 85-150 mg daily for 35 days after HA and 14 days after KA
Number of subjects: 0
Study 34429127 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH, enoxaparin), 40 mg, subcutaneously, daily within 24 hours postoperatively for 35 days after HA and 14 days after KA
Number of subjects: 0
Study 34429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 34429127 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 0
Study 32776763 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy (superficial heat, transcutaneous electrical nerve stimulation, pulsed ultrasound)
Number of subjects: 120
Study 32776763 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum neurotoxin type A (single intra-articular injection)
Number of subjects: 120
Study 32776763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (three intra-articular injections)
Number of subjects: 120
Study 32776763 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% dextrose (three intra-articular injections)
Number of subjects: 120
Study 34706982 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 108
Study 34706982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 33259790 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime eating schedule (0800 h-1900 h)
Number of subjects: 12
Study 33259790 — intervention group
Group type: COMPARATOR
Intervention: Delayed eating schedule (1200 h-2300 h)
Number of subjects: 12
Study 32733445 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir gel
Number of subjects: 48
Study 35640598 — intervention group
Group type: EXPERIMENTAL
Intervention: High Brazilian green propolis dose (H‐BGP)
Number of subjects: 18
Study 35640598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 35640598 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Brazilian green propolis dose
Number of subjects: 18
Study 32090117 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with glucose fluctuation targeted intervention, targeting hemoglobin A1c (HbA1c) < 7%.
Number of subjects: 75
Study 32090117 — intervention group
Group type: COMPARATOR
Intervention: Usual care focused on hemoglobin A1c (HbA1c) control, targeting A1c < 7%.
Number of subjects: 75
Study 32105342 — intervention group
Group type: EXPERIMENTAL
Intervention: Total magnesium intake (diet + supplements)
Number of subjects: 104025
Study 32105342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary magnesium intake
Number of subjects: 104025
Study 35209777 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished patients (n = 14)
Number of subjects: 58
Study 35209777 — intervention group
Group type: COMPARATOR
Intervention: Well-nourished patients (n = 44)
Number of subjects: 58
Study 35209777 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional screening protocols MUST and NRS-2002
Number of subjects: 58
Study 35209777 — intervention group
Group type: EXPERIMENTAL
Intervention: UICC classification and HPV status
Number of subjects: 58
Study 34259406 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint thread-embedding applied at Ganshu (BL 18), Pishu (BL 20), Shenshu (BL 23), Zusanli (ST 36), Guangming (GB 37), once every 2 weeks for 2 months
Number of subjects: 60
Study 34259406 — intervention group
Group type: COMPARATOR
Intervention: Control group received comprehensive therapy of eye covering of intact side and family refined performance
Number of subjects: 60
Study 36139151 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 92
Study 36139151 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 92
Study 34506608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab with or without corticosteroids
Number of subjects: 412
Study 34506608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab without corticosteroids
Number of subjects: 412
Study 34506608 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) only
Number of subjects: 412
Study 34506608 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC plus corticosteroid
Number of subjects: 412
Study 34506608 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC plus tocilizumab
Number of subjects: 412
Study 34506608 — intervention group
Group type: EXPERIMENTAL
Intervention: SoC plus tocilizumab and corticosteroid
Number of subjects: 412
Study 36170303 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐mm diameter healing abutment (group 1)
Number of subjects: 246
Study 36170303 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐mm diameter healing abutment (group 2)
Number of subjects: 246
Study 36170303 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5‐mm diameter healing abutment (group 3)
Number of subjects: 246
Study 36170303 — intervention group
Group type: EXPERIMENTAL
Intervention: Provisional restoration (group 4)
Number of subjects: 246
Study 36170303 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized healing abutment (group 5)
Number of subjects: 246
Study 33622047 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care coverage
Number of subjects: 178
Study 35791083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat
Number of subjects: 731
Study 35791083 — intervention group
Group type: COMPARATOR
Intervention: Sacubitril/Valsartan
Number of subjects: 731
Study 32649326 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person interpreter
Number of subjects: 106
Study 32649326 — intervention group
Group type: COMPARATOR
Intervention: Phone interpreter
Number of subjects: 106
Study 32178655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment
Number of subjects: 200
Study 32178655 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 200
Study 33125902 — intervention group
Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy with suture
Number of subjects: 0
Study 33125902 — intervention group
Group type: COMPARATOR
Intervention: Coblation tonsillectomy without suture
Number of subjects: 0
Study 32875638 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) membrane
Number of subjects: 117
Study 32875638 — intervention group
Group type: COMPARATOR
Intervention: Native collagen membrane (BG)
Number of subjects: 117
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medication use
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulants
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-deficit/hyperactivity disorder (ADHD)
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive functioning
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hispanic White ethnicity
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-2 agonists
Number of subjects: 202
Study 34855690 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 202
Study 32015031 — intervention group
Group type: EXPERIMENTAL
Intervention: CSJ148 (combination of LJP538 and LJP539)
Number of subjects: 0
Study 32015031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32015031 — intervention group
Group type: EXPERIMENTAL
Intervention: CSJ148
Number of subjects: 0
Study 616443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (first, second, and third trimesters)
Number of subjects: 125
Study 616443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (first trimester)
Number of subjects: 125
Study 616443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (second trimester)
Number of subjects: 125
Study 616443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (third trimester)
Number of subjects: 125
Study 616443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (first two trimesters)
Number of subjects: 125
Study 616443500 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women (throughout gestation)
Number of subjects: 125
Study 616443500 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women (control)
Number of subjects: 125
Study 36070207 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal stress lability
Number of subjects: 72
Study 36070207 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and mean stress
Number of subjects: 72
Study 34155534 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder group (N=51)
Number of subjects: 102
Study 34155534 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy
Number of subjects: 102
Study 34155534 — intervention group
Group type: COMPARATOR
Intervention: No-reminder group (N=51)
Number of subjects: 102
Study 32988459 — intervention group
Group type: EXPERIMENTAL
Intervention: AES-scored multi-prompt writing screener
Number of subjects: 559
Study 32988459 — intervention group
Group type: EXPERIMENTAL
Intervention: AES-scored screener with fewer prompts
Number of subjects: 559
Study 32988459 — intervention group
Group type: COMPARATOR
Intervention: Screeners scored for word count
Number of subjects: 559
Study 35781184 — intervention group
Group type: EXPERIMENTAL
Intervention: Voiding cystourethrograms (VCUGs) recommended and obtained more frequently in patients <2-months-old
Number of subjects: 137
Study 35781184 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinalysis and urine culture diagnostic criteria
Number of subjects: 137
Study 35781184 — intervention group
Group type: EXPERIMENTAL
Intervention: UTI recurrence
Number of subjects: 137
Study 35781184 — intervention group
Group type: EXPERIMENTAL
Intervention: fUTI recurrence
Number of subjects: 137
Study 35781184 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day readmission
Number of subjects: 137
Study 35781184 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day ED revisit
Number of subjects: 137
Study 33667442 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441
Study 33667442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 35012511 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on vaccination
Number of subjects: 863
Study 34301978 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-learning framework for analyzing fatty infiltration using automated region-based Otsu thresholding technique
Number of subjects: 240
Study 34301978 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty infiltration measure using Otsu thresholding method
Number of subjects: 240
Study 34301978 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation ratio and fatty infiltration using Otsu thresholding
Number of subjects: 240
Study 35964471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Number of subjects: 0
Study 35964471 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab 10 mg/kg every 3 weeks for 4 doses and then every 12 weeks, intravenously ≤1 year
Number of subjects: 0
Study 35964471 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 35964471 — intervention group
Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 0
Study 33108932 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT‐I)
Number of subjects: 28
Study 33108932 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 28
Study 32554837 — intervention group
Group type: EXPERIMENTAL
Intervention: Qurs-e-Gulnar, 3 Qurs twice a day for 45 days
Number of subjects: 40
Study 32554837 — intervention group
Group type: COMPARATOR
Intervention: Diabeat®, 2 capsules twice a day for 45 days
Number of subjects: 40
Study 32554837 — intervention group
Group type: EXPERIMENTAL
Intervention: Qurs-e-Gulnar
Number of subjects: 40
Study 32554837 — intervention group
Group type: COMPARATOR
Intervention: Diabeat®
Number of subjects: 40
Study 35869349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 452
Study 34607885 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting during rounds
Number of subjects: 99
Study 34607885 — intervention group
Group type: COMPARATOR
Intervention: Standing during rounds
Number of subjects: 99
Study 33202416 — intervention group
Group type: EXPERIMENTAL
Intervention: LRYGB
Number of subjects: 16
Study 33202416 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 16
Study 35952629 — intervention group
Group type: EXPERIMENTAL
Intervention: HP + LFHD
Number of subjects: 438
Study 35952629 — intervention group
Group type: EXPERIMENTAL
Intervention: HP + HFHD
Number of subjects: 438
Study 35952629 — intervention group
Group type: COMPARATOR
Intervention: LFHD
Number of subjects: 438
Study 35952629 — intervention group
Group type: COMPARATOR
Intervention: HFHD
Number of subjects: 438
Study 33856418 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gene genomic classifier
Number of subjects: 0
Study 32867965 — intervention group
Group type: EXPERIMENTAL
Intervention: FSE diet (basal diet + 100 mg/kg FSE)
Number of subjects: 192
Study 35791025 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32892481 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser (10 600 nm)
Number of subjects: 20
Study 32892481 — intervention group
Group type: COMPARATOR
Intervention: 50% trichloroacetic acid (TCA)
Number of subjects: 20
Study 36332141 — intervention group
Group type: EXPERIMENTAL
Intervention: STEPS 1.1 module
Number of subjects: 15
Study 36332141 — intervention group
Group type: COMPARATOR
Intervention: Control module
Number of subjects: 15
Study 34907421 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 40
Study 34907421 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 40
Study 32217275 — intervention group
Group type: EXPERIMENTAL
Intervention: Midfoot joint mobilization and home exercise program (HEP)
Number of subjects: 0
Study 32217275 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment and home exercise program (HEP)
Number of subjects: 0
Study 35569003 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus probiotics
Number of subjects: 150
Study 35569003 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus probiotics and dietary fiber
Number of subjects: 150
Study 35569003 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 150
Study 33479080 — intervention group
Group type: EXPERIMENTAL
Intervention: Hub-and-spoke thrombectomy service in routine UK 24/7 clinical practice
Number of subjects: 0
Study 33479080 — intervention group
Group type: COMPARATOR
Intervention: Patients accepted for transfer to the thrombectomy centre
Number of subjects: 0
Study 33479080 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy cases performed outside of standard working hours
Number of subjects: 0
Study 33726537 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Nepafenac
Number of subjects: 38
Study 33726537 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal Ranibizumab
Number of subjects: 38
Study 33726537 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic treatment)
Number of subjects: 38
Study 34528220 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 µg twice daily
Number of subjects: 3589
Study 34528220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3589
Study 36332827 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg/70 kg)
Number of subjects: 96
Study 36332827 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (50 mg diphenhydramine)
Number of subjects: 96
Study 33106970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube current of 13 mA
Number of subjects: 30
Study 33106970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube current of 10 mA
Number of subjects: 30
Study 33106970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube current of 7 mA
Number of subjects: 30
Study 32513277 — intervention group
Group type: EXPERIMENTAL
Intervention: Household drinking water disinfection by chlorination (1.2% sodium hypochlorite)
Number of subjects: 405
Study 32513277 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual habits of water collection and storage)
Number of subjects: 405
Study 35794485 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic mindsets intervention (self-administered online training module)
Number of subjects: 3410
Study 35794485 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic mindsets intervention
Number of subjects: 3410
Study 33844587 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-facilitated lingual exercise regimen
Number of subjects: 0
Study 36042425 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity trackers (WATs) with a mobile application for 12 weeks
Number of subjects: 18
Study 36042425 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital support in OA care
Number of subjects: 18
Study 34570054 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual feedback about bedtime, wake time, and sleep duration
Number of subjects: 15
Study 34570054 — intervention group
Group type: COMPARATOR
Intervention: No individual feedback
Number of subjects: 15